Detecting and genotyping high-risk human papillomavirus among male patients during 2015-2023 in Beijing, China

Few studies focused on human papillomavirus (HPV) in male patients. This study aimed to explore the detection rate and genotyping of HPV among male patients in Beijing to provide a reference for formulating prevention strategies for HPV infection. The cross-sectional study was conducted in Beijing C...

Full description

Saved in:
Bibliographic Details
Published in:Emerging microbes & infections 2024-12, Vol.13 (1), p.2313848-2313848
Main Authors: Wang, Shuai, Ma, Qin-Yi, Du, Juan, Wei, Ting-Ting, Zhang, Wan-Xue, Wang, Peng, Zhou, Yiguo, Wei, Ming, Gu, Li, Cui, Fuqiang, Lu, Qing-Bin
Format: Article
Language:English
Subjects:
Beijing - epidemiology
China
China - epidemiology
Cross-Sectional Studies
Dermatology
Genotype
Human papillomavirus
Human Papillomavirus Viruses
Humans
Infections
Male
Papillomaviridae - genetics
Papillomavirus Infections - diagnosis
Papillomavirus Infections - epidemiology
Papillomavirus Infections - prevention & control
Prevalence
Urology
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Few studies focused on human papillomavirus (HPV) in male patients. This study aimed to explore the detection rate and genotyping of HPV among male patients in Beijing to provide a reference for formulating prevention strategies for HPV infection. The cross-sectional study was conducted in Beijing Chaoyang Hospital from November 2015 to March 2023. It covered male patients from the urology and dermatology departments. Fifteen high-risk HPV genotypes were detected by the multiplex real-time polymerase chain reaction method. The overall detection rate of HPV was 25.19% (1288/5114, 95% confidence interval [CI] 24.00%-26.38%), of which the single infection rate was 16.99% (869/5114, 95% CI 15.97%-18.05%) and the co-infection rate was 8.19% (419/5114, 95% CI 7.46%-8.98%). The detection rate of HPV was 40.77% (521/1278), 35.58% (58/163), 32.69% (101/309), 31.91% (60/188), 12.63% (299/2367), and 32.35% (131/405) among male patients with balanitis, warts, rash, urethritis, prostatitis, and other urinary inflammation, respectively (  
ISSN:2222-1751
2222-1751
DOI:10.1080/22221751.2024.2313848